Ambrose JA. Plaque disruption and the acute coronary syndromes of unstable angina
and myocardial infarction: if the substrate is similar, why is the clinical
presentation different? J Am Coll Cardiol.1992;19:1653-1658.
Ambrose JA, Weinrauch M. Thrombosis in ischemic heart disease. Arch Intern Med.1996;156:1382-1394.
Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation.2001;104:365-372.
DeWood MA, Spores J, Notske R.
et al. Prevalence of total coronary occlusion during the early hours of transmural
myocardial infarction. N Engl J Med.1980;303:897-902.
Davies MJ, Thomas A. Plaque fissuring—the cause of acute myocardial infarction, sudden
ischemic death, and crescendo angina. Br Heart J.1985;53:363-373.
Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina
suffering sudden ischemic cardiac death. Circulation.1986;73:418-427.
Ardissino D, Merlini PA, Arlens R.
et al. Tissue factor in human coronary atherosclerotic plaques. Clin Chim Acta.2000;291:235-240.
Weitz JI. Activation of blood coagulation by plaque rupture: mechanisms and prevention. Am J Cardiol.1995;75:18B-22B.
Antman EM. The search for replacements for unfractionated heparin. Circulation.2001;103:2310-2314.
Harenberg J. Pharmacology of low molecular weight heparins. Semin Thromb Hemost.1990;16(suppl):12-18.
Weitz JI. Low-molecular-weight heparins. N Engl J Med.1997;337:688-698.
Boneu B. Low molecular weight heparin therapy: is monitoring needed? Thromb Haemost.1994;72:330-334.
Abbate R, Gori AM, Farsi A, Attanasio M, Pepe G. Monitoring of low-molecular-weight heparins in cardiovascular disease. Am J Cardiol.1998;82:33L-36L.
Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy.2001;21:218-234.
Bastani B, Gonzalez E. Prolonged anti-factor Xa level in a patient with moderate renal insufficiency
receiving enoxaparin. Am J Nephrol.2002;22:403-404.
Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin
enoxaparin sodium during pregnancy. Am J Obstet Gynecol.1999;181:1113-1117.
The FRAXIS Investigators. Comparison of two treatment durations (6 days and 14 days) of a low
molecular weight heparin with a 6-day treatment of unfractionated heparin
in the initial management of unstable angina or non-Q wave myocardial infarction:
FRAXIS (FRAxiparine in Ischaemic Syndrome). Eur Heart J.1999;20:1553-1562.
Antman EM, McCabe CH, Gurfinkel EP.
et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non–Q-wave
myocardial infarction: results of the thrombolysis in myocardial infarction
(TIMI) 11B trial. Circulation.1999;100:1593-1601.
Cohen M, Demers C, Gurfinkel EP.
et al. A comparison of low-molecular-weight heparin with unfractionated heparin
for unstable coronary artery disease: Efficacy and Safety of Subcutaneous
Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med.1997;337:447-452.
Klein W, Buchwald A, Hillis SE.
et al. Comparison of low-molecular-weight heparin with unfractionated heparin
acutely and with placebo for 6 weeks in the management of unstable coronary
artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation.1997;96:61-68.
Antman EM, Cohen M, Radley D.
et al. Assessment of the treatment effect of enoxaparin for unstable angina/non–Q-wave
myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation.1999;100:1602-1608.
Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome: evidence for
superior or equivalent efficacy compared with unfractionated heparin? J Am Coll Cardiol.2000;35:1699-1712.
Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary
syndrome without ST elevation: a meta-analysis. Lancet.2000;355:1936-1942.
Michalis LK, Katsouras C, Papamichael N.
et al. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary
syndromes: the EVET trial. Am Heart J.In press.
Cohen M, Theroux P, Weber S.
et al. Combination therapy with tirofiban and enoxaparin in acute coronary
syndromes. Int J Cardiol.1999;71:273-281.
Boersma E, Harrington RA, Moliterno DJ.
et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes:
a meta-analysis of all major randomised clinical trials. Lancet.2002;359:189-198.
Cohen M. The Treatment with Enoxaparin and Tirofiban in Acute Myocardial Infarction
(TETAMI) Study. Paper presented at: American Heart Association 75th Scientific Sessions;
November 17-20, 2002; Chicago, Ill.
Merlini PA, Bauer KA, Oltrona L.
et al. Persistent activation of coagulation mechanism in unstable angina and
myocardial infarction. Circulation.1994;90:61-68.
Ernofsson M, Strekerud F, Toss H, Abildgaard U, Wallentin L. Low molecular weight heparin reduces the generation and activity of
thrombin in unstable coronary artery disease. Thromb Haemost.1998;79:491-494.
Merlini PA, Ardissino D, Rosenberg RD.
et al. In vivo thrombin generation and activity during and after intravenous
infusion of heparin or recombinant hirudin in patients with unstable angina
pectoris. Arterioscler Thromb Vasc Biol.2000;20:2162-2166.
The FRISC Study Group. Low-molecular-weight heparin during instability in coronary artery
disease: Fragmin During Instability in Coronary Artery Disease (FRISC) Study
Antman EM, Cohen M, McCabe C, Goodman SG, Murphy SA, Braunwald E. Enoxaparin is superior to unfractionated heparin for preventing clinical
events at 1-year follow-up of TIMI 11B and ESSENCE. Eur Heart J.2002;23:308-314.
The FRISC II Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease:
FRISC II prospective randomised multicentre study. Lancet.1999;354:701-707.
The FRISC II Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery
disease: FRISC II prospective randomised multicentre study: Fragmin and Fast
Revascularisation During Instability in Coronary Artery Disease Investigators. Lancet.1999;354:708-715.
Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease
who benefit from long-term antithrombotic protection: Fragmin in Unstable
Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol.1997;29:43-48.
Lindahl B, Diderholm E, Lagerqvist B, Venge P, Wallentin L. Mechanisms behind the prognostic value of troponin T in unstable coronary
artery disease: a FRISC II substudy. J Am Coll Cardiol.2001;38:979-986.
Antman EM, Cohen M, Bernink PJ.
et al. The TIMI risk score for unstable angina/non–ST-elevation MI:
a method for prognostication and therapeutic decision making. JAMA.2000;284:835-842.
Fox K, Antman E, Cohen M, Bigonzi F. Comparison of enoxaparin versus unfractionated heparin in patients
with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction
having subsequent percutaneous coronary intervention. Am J Cardiol.2002;90:477-482.
Seitz R, Pelzer H, Immel A. Prothrombin activation by thrombolytic agents. Fibrinolysis.1993;7:109-115.
Eisenberg PR, Sherman L, Rich M.
et al. Importance of continued activation of thrombin reflected by fibrinopeptide
A to the efficacy of thrombolysis. J Am Coll Cardiol.1986;7:1255-1262.
Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase: evidence
for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol.1987;10:527-529.
Fitzgerald DJ, Catella F, Roy L, FitzGerald GA. Marked platelet activation in vivo after intravenous streptokinase
in patients with acute myocardial infarction. Circulation.1988;77:142-150.
Coulter SA, Cannon CP, Ault KA.
et al. High levels of platelet inhibition with abciximab despite heightened
platelet activation and aggregation during thrombolysis for acute myocardial
infarction: results from TIMI (Thrombolysis in Myocardial Infarction) 14. Circulation.2000;101:2690-2695.
Kerins DM, Roy L, FitzGerald GA, Fitzgerald DJ. Platelet and vascular function during coronary thrombolysis with tissue-type
plasminogen activator. Circulation.1989;80:1718-1725.
Simoons M, Krzeminska-Pakula M, Alonso A.
et al. Improved reperfusion and clinical outcome with enoxaparin as an adjunct
to streptokinase thrombolysis in acute myocardial infarction: the AMI-SK study. Eur Heart J.2002;23:1282.
Ross AM, Molhoek P, Lundergan C.
et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin,
with unfractionated heparin adjunctive to recombinant tissue plasminogen activator
thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion
Therapy (HART II). Circulation.2001;104:648-652.
Antman EM, Louwerenburg HW, Baars HF.
et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial
infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI)
23 Trial. Circulation.2002;105:1642-1649.
Frostfeldt G, Ahlberg G, Gustafsson G.
et al. Low molecular weight heparin (dalteparin) as adjuvant treatment of
thrombolysis in acute myocardial infarction—a pilot study: Biochemical
Markers in Acute Coronary Syndromes (BIOMACS II). J Am Coll Cardiol.1999;33:627-633.
Wallentin L, Dellborg DM, Lindahl B, Nilsson T, Pehrsson K, Swahn E. The low-molecular-weight heparin dalteparin as adjuvant therapy in
acute myocardial infarction: the ASSENT PLUS study. Clin Cardiol.2001;24(3 suppl):I12-I14.
Tatu-Chitoiu G, Tatu-Chitoiu A, Bumbu A.
et al. Accelerated streptokinase and enoxaparine: a new thrombolytic regimen
in acute myocardial infarction (the ASENOX study) [abstract]. Eur Heart J.2000;21(suppl):177.
Baird SH, Menown IB, McBride SJ, Trouton TG, Wilson C. Randomized comparison of enoxaparin with unfractionated heparin following
fibrinolytic therapy for acute myocardial infarction. Eur Heart J.2002;23:627-632.
Wallentin L. ASSENT 3 PLUS. Paper presented at: American Heart Association 75th Scientific Sessions;
November 17-20; 2002; Chicago, Ill.
Cannon CP, Weintraub WS, Demopoulos LA.
et al. Comparison of early invasive and conservative strategies in patients
with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor
tirofiban. N Engl J Med.2001;344:1879-1887.
Zijlstra F, Hoorntje JC, de Boer MJ.
et al. Long-term benefit of primary angioplasty as compared with thrombolytic
therapy for acute myocardial infarction. N Engl J Med.1999;341:1413-1419.
Bertrand ME, Simoons M, Fox KA. Management of acute coronary syndromes: acute coronary syndromes without
persistent ST segment elevation; recommendations of the Task Force of the
European Society of Cardiology. Eur Heart J.2000;21:1406-1432.
Cairns JA, Theroux P, Lewis Jr HD, Ezekowitz M, Meade TW. Antithrombotic agents in coronary artery disease. Chest.2001;119(1 suppl):228S-252S.
Braunwald E, Antman EM, Beasley JW.
et al. ACC/AHA 2002 guideline update for the management of patients with unstable
angina and non-ST-segment elevation myocardial infarction: a report of the
American College of Cardiology/American Heart Association Task Force on Practice
Guidelines (Committee of the Management of Patients With Unstable Angina). Available at: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf. Accessed November 29, 2002.
Melandri G, Branzi A, Traini AM, Semprini F, Cervi V, Magnani B. On the value of the activated clotting time for monitoring heparin
therapy in acute coronary syndromes. Am J Cardiol.1993;71:469-471.
Gram J, Mercker S, Bruhn HD. Does protamine chloride neutralize low molecular weight heparin sufficiently? Thromb Res.1988;52:353-359.
Kereiakes DJ, Montalescot G, Antman EM.
et al. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary
syndromes and during percutaneous coronary intervention: an expert consensus. Am Heart J.2002;144:615-624.
The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI
11A. J Am Coll Cardiol.1997;29:1474-1482.
Goodman S, Cohen M, Bigonzi F. Randomized trial of low molecular weight heparin (enoxaparin) versus
unfractionated heparin for unstable coronary artery disease: one-year results
of the ESSENCE Study: Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q
Wave Coronary Events. J Am Coll Cardiol.2000;36:693-698.
Bassand JP. Low molecular weight heparin in patients undergoing interventional
therapy: the ANGIOFRAX study [in German]. Paper presented at: XXIInd Congress of the European Society of Cardiology;
August 26-30, 2000; Amsterdam, the Netherlands.
Karsch KR, Preisack MB, Baildon R.
et al. Low molecular weight heparin (reviparin) in percutaneous transluminal
coronary angioplasty: results of a randomized, double-blind, unfractionated
heparin and placebo-controlled, multicenter trial (REDUCE trial): Reduction
of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind
Unfractionated Heparin and Placebo-Controlled Evaluation. J Am Coll Cardiol.1996;28:1437-1443.
Rabah MM, Premmereur J, Graham M.
et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention
in stable angina pectoris. Am J Cardiol.1999;84:1391-1395.
Cohen M, Theroux P, Borzak S.
et al. Randomized double-blind safety study of enoxaparin versus unfractionated
heparin in patients with non-ST-segment elevation acute coronary syndromes
treated with tirofiban and aspirin: the ACUTE II study: the Antithrombotic
Combination Using Tirofiban and Enoxaparin. Am Heart J.2002;144:470-477.
Collet JP, Montalescot G, Lison L.
et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment
in patients with unstable angina pectoris. Circulation.2001;103:658-663.
Kereiakes DJ, Grines C, Fry E.
et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous
coronary intervention. J Invasive Cardiol.2001;13:272-278.
Mukherjee D, Mahaffey KW, Moliterno DJ.
et al. Promise of combined low-molecular-weight heparin and platelet glycoprotein
IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction
of Acute coronary syndrome events in a Global Organization Network B (PARAGON
B). Am Heart J.2002;144:995-1002.
Kereiakes DJ, Kleiman NS, Fry E.
et al. Dalteparin in combination with abciximab during percutaneous coronary
intervention. Am Heart J.2001;141:348-352.
Ferguson JJ. The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes;
including PCI: final results of the NICE 3 study. J Am Coll Cardiol.2001;37(suppl A):365A.
Martin JL, Fry ET, Serano A. Pharmacokinetic study of enoxaparin in patients undergoing coronary
intervention after treatment with subcutaneous enoxaparin in acute coroanry
syndromes: the PEPCI Study [abstract]. Eur Heart J.2001;22(suppl):14.
Choussat R, Montalescot G, Collet JP.
et al. A unique, low dose of intravenous enoxaparin in elective percutaneous
coronary intervention. J Am Coll Cardiol.2002;40:1943-1950.
Blazing MA, De Lemos JA, Dyke CK, Califf RM, Bilheimer D, Braunwald E. The A-to-Z Trial: methods and rationale for a single trial investigating
combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa
inhibitor tirofiban and defining the efficacy of early aggressive simvastatin
therapy. Am Heart J.2001;142:211-217.
The SYNERGY Executive Committee. The SYNERGY trial: study design and rationale. Am Heart J.2002;143:952-960.
Smith Jr SC, Dove JT, Jacobs AK.
et al. ACC/AHA guidelines for percutaneous coronary intervention: a report
of the American College of Cardiology/American Heart Association Task Force
on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous
transluminal coronary angioplasty). J Am Coll Cardiol.2001;37:2215-2239.
Bhatt DL, Lee BI, Casterella PJ.
et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients
undergoing percutaneous coronary intervention—results of the CRUISE
study. J Am Coll Cardiol.In press.
Barzu T, Molho P, Tobelem G, Petitou M, Caen J. Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta.1985;845:196-203.
Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit
less binding to plasma proteins than unfractionated heparin. Thromb Haemost.1994;71:300-304.
Bara L, Billaud E, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of a low molecular weight heparin (PK
10 169) and unfractionated heparin after intravenous and subcutaneous
administration. Thromb Res.1985;39:631-636.
Bara L, Bloch MF, Zitoun D.
et al. Comparative effects of enoxaparin and unfractionated heparin in healthy
volunteers on prothrombin consumption in whole blood during coagulation, and
release of tissue factor pathway inhibitor. Thromb Res.1993;69:443-452.
Merlini PA, Bauer KA, Oltrona L.
et al. Thrombin generation and activity during thrombolysis and concomitant
heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol.1995;25:203-209.
Sandset PM, Bendz B, Hansen JB. Physiological function of tissue factor pathway inhibitor and interaction
with heparins. Haemostasis.2000;30(suppl 2):48-56.
Hansen JB, Sandset PM. Differential effects of low molecular weight heparin and unfractionated
heparin on circulating levels of antithrombin and tissue factor pathway inhibitor
(TFPI): a possible mechanism for difference in therapeutic efficacy. Thromb Res.1998;91:177-181.
Hansen JB, Sandset PM, Huseby KR.
et al. Differential effect of unfractionated heparin and low molecular weight
heparin on intravascular tissue factor pathway inhibitor: evidence for a difference
in antithrombotic action. Br J Haematol.1998;101:638-646.
Hansen JB, Naalsund T, Sandset PM, Svensson B. Rebound activation of coagulation after treatment with unfractionated
heparin and not with low molecular weight heparin is associated with partial
depletion of tissue factor pathway inhibitor and antithrombin. Thromb Res.2000;100:413-417.
Cella G, Girolami A, Sasahara AA. Platelet activation with unfractionated heparin at therapeutic concentrations
and comparison with low-molecular-weight heparin and with a direct thrombin
Montalescot G, Philippe F, Ankri A.
et al. Early increase of von Willebrand factor predicts adverse outcome in
unstable coronary artery disease: beneficial effects of enoxaparin: French
Investigators of the ESSENCE Trial. Circulation.1998;98:294-299.
Morrow DA, Rifai N, Bigonzi F.
et al. Enoxaparin attenuates the rise in Von wilebrand factor in patients
with ST-segment elevation myocardial infarction treated with fibrinolysis:
results from ENTIRE-TIMI 23. Eur Heart J.2002;23(suppl):506.
Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations
and comparisons with a low-molecular-weight heparin and with a direct thrombin
Serra A, Esteve J, Reverter JC, Lozano M, Escolar G, Ordinas A. Differential effect of a low-molecular-weight heparin (dalteparin)
and unfractionated heparin on platelet interaction with the subendothelium
under flow conditions. Thromb Res.1997;87:405-410.
James S, Armstrong P, Califf R.
et al. Safety and efficacy of abciximab combined with dalteparin in treatment
of acute coronary syndromes. Eur Heart J.2002;23:1538-1545.
Goodman S. Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndromes
Treatment (INTERACT). Paper presented at: American College of Cardiology 51st Annual Scientific
Session; March 17-20, 2002; Atlanta, Ga.
Kontny F, Dale J, Abildgaard U, Pedersen TR. Randomized trial of low molecular weight heparin (dalteparin) in prevention
of left ventricular thrombus formation and arterial embolism after acute anterior
myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI)
Study. J Am Coll Cardiol.1997;30:962-969.
The ASSENT 3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin,
abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute
myocardial infarction. Lancet.2001;358:605-613.